BIAFHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 12 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores bioAffinity Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BIAF, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Apr 2025 | Maxim Group | Downgrade | Hold | — |
| 23 July 2024 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIAF appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 82% of US stocks
Cheaper than 77% of US stocks
Cheaper than 62% of US stocks
Higher than 69% of US stocks
Higher than 17% of US stocks
Higher than 37% of US stocks
Higher than 10% of US stocks
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 2% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own bioAffinity Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
bioAffinity Technologies reported its second quarter 2026 financial results and highlighted continued strong commercial momentum for its CyPath Lung test for lung cancer.
Why it matters — BIAF watchers would care because the report signals ongoing commercial progress for the company's core CyPath Lung product.
bioAffinity Technologies published a white paper on CyPath® Lung that presents clinical protocols for lung nodule evaluation, lung cancer patient care, and survivor surveillance.
Why it matters — The release of clinical protocols for CyPath® Lung could help position the company's diagnostic approach in the growing market for lung cancer detection and risk stratification.
Zacks Investment Research published a comparison of bioAffinity Technologies (BIAF) and Biodesix (BDSX), two cancer diagnostics stocks with different strategies, examining which offers better long-term upside.
Why it matters — The article provides a direct competitive analysis between BIAF and another oncology diagnostics company, which may help investors understand BIAF's positioning in the cancer diagnostics space.
Of the 1 analysts covering bioAffinity Technologies, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks bioAffinity Technologies, Inc. 15 out of 100 across roughly 4,600 US stocks as at 12 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Aug 2026, bioAffinity Technologies, Inc. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering bioAffinity Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIAF are extrapolating price history, which says nothing about the business.
bioAffinity Technologies, Inc. returned -94.2% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
BioAffinity Technologies Inc. is a biotechnology company specializing in noninvasive diagnostics and targeted cancer therapeutics for early-stage lung cancer and other lung diseases.
The most recent item we track (Business Wire, 7 Aug 2026): "bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung". bioAffinity Technologies reported its second quarter 2026 financial results and highlighted continued strong commercial momentum for its CyPath Lung test for lung cancer.
BioAffinity Technologies Inc. is a biotechnology company specializing in noninvasive diagnostics and targeted cancer therapeutics for early-stage lung cancer and other lung diseases. Its flagship product, CyPath Lung, employs flow cytometry technology and automated AI analysis to examine sputum samples, identifying cell populations indicative of malignancy, including cancer cells shed from lung tumors. This enables early detection in high-risk patients, potentially reducing the need for invasive biopsies. The company operates through Diagnostic Research and Development and Laboratory Services segments, with its Precision Pathology Laboratory Services providing anatomic and clinical pathology support. BioAffinity Technologies Inc. also advances its platform technology for applications in asthma and COPD, such as matching patients to biologic therapies by detecting antibody drug receptors in sputum. Additionally, through its subsidiary OncoSelect Therapeutics, it researches porphyrin-based therapies that selectively target and kill cancer cells. Founded in 2014 and headquartered in San Antonio, Texas, BioAffinity Technologies Inc. plays a key role in the in vitro diagnostics sector of healthcare, addressing critical needs in oncology and respiratory medicine.
CEO Ms. Maria Zannes J.D. · 57 employees · United States · https://bioaffinitytech.com